Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: A network meta-analysis
Best L. M. J., Freeman S. C., Sutton A. J., Cooper N. J., Tng E. -., Csenar M., Hawkins N., Pavlov Ch. S., Davidson B. R., Thorburn D., Cowlin M., Janemilne E., Tsochatzis E., Gurusamy' K. S.
Cochrane database of systematic reviews (Online : Update Software)
Vol.2019, Issue9, Num.CD013103
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1002/14651858.CD013103.pub2
Аннотация:
Background Hepatorenal syndrome is defined as renal failure in people with cirrhosis in the absence of other causes. In addition to supportive treatment such as albumin to restore fluid balance, the other potential treatments include systemic vasoconstrictor drugs (such as vasopressin analogues or noradrenaline), renal vasodilator drugs (such as dopamine), transjugular intrahepatic portosystemic shunt (TIPS), and liver support with molecular adsorbent recirculating system (MARS). There is uncertainty over the best treatment regimen for hepatorenal syndrome. Objectives To compare the benefits and harms of different treatments for hepatorenal syndrome in people with decompensated liver cirrhosis. Search methods We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and trial registers until December 2018 to identify randomised clinical trials on hepatorenal syndrome in people with cirrhosis. Select
Ключевые слова:
albumin; midodrine; noradrenalin; octreotide; terlipressin; vasoconstrictor agent; clinical effectiveness; clinical feature; decompensated liver cirrhosis; drug effect; drug efficacy; drug response; evidence based practice; follow up; health care cost; hepatorenal syndrome; human; intervention study; liver transplantation; meta analysis; mortality rate; priority journal; quality of life; Review; treatment outcome; adult; Bayes theorem; complication; female; hepatorenal syndrome; liver cirrhosis; male; middle aged; network meta-analysis; quality of life; randomized controlled trial (topic); Adult; Bayes Theorem; Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Vasoconstrictor Agents
Язык текста: Английский
ISSN: 1361-6137
Best L. M. J.
Freeman S. C.
Sutton A. J.
Cooper N. J.
Tng E. -. E.-L.
Csenar M.
Hawkins N.
Pavlov Ch. S. Chavdar Savov 1967-
Davidson B. R.
Thorburn D.
Cowlin M.
Janemilne E.
Tsochatzis E.
Gurusamy' K. S. Kurinchi Sel`van 1973-
Бест Л. М. Й.
Фрееман С. C.
Суттон А. Й.
Cоопер Н. Й.
Тнг Е. -. Е.-Л.
Cсенар М.
Хаwкинс Н.
Павлов Ч. С. Чавдар Савов 1967-
Давидсон Б. Р.
Тхорбурн Д.
Cоwлин М.
Йанемилне Е.
Цочатзис Е.
Гурусамы К. С. Куринчи Сельван 1973-
Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: A network meta-analysis
Текст визуальный непосредственный
Cochrane database of systematic reviews (Online : Update Software)
Wiley
Vol.2019, Issue9 Num.CD013103
2019
Обзор
albumin midodrine noradrenalin octreotide terlipressin vasoconstrictor agent clinical effectiveness clinical feature decompensated liver cirrhosis drug effect drug efficacy drug response evidence based practice follow up health care cost hepatorenal syndrome human intervention study liver transplantation meta analysis mortality rate priority journal quality of life Review treatment outcome adult Bayes theorem complication female hepatorenal syndrome liver cirrhosis male middle aged network meta-analysis quality of life randomized controlled trial (topic) Adult Bayes Theorem Female Hepatorenal Syndrome Humans Liver Cirrhosis Liver Transplantation Male Middle Aged Network Meta-Analysis Quality of Life Randomized Controlled Trials as Topic Vasoconstrictor Agents
Background Hepatorenal syndrome is defined as renal failure in people with cirrhosis in the absence of other causes. In addition to supportive treatment such as albumin to restore fluid balance, the other potential treatments include systemic vasoconstrictor drugs (such as vasopressin analogues or noradrenaline), renal vasodilator drugs (such as dopamine), transjugular intrahepatic portosystemic shunt (TIPS), and liver support with molecular adsorbent recirculating system (MARS). There is uncertainty over the best treatment regimen for hepatorenal syndrome. Objectives To compare the benefits and harms of different treatments for hepatorenal syndrome in people with decompensated liver cirrhosis. Search methods We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and trial registers until December 2018 to identify randomised clinical trials on hepatorenal syndrome in people with cirrhosis. Select